Moxzole

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Moxzole

Quick Facts

Property Description
Active Ingredients Sulphamethoxazole, Trimethoprim
Form Tablet, Oral Suspension, Intravenous Solution
Pharmacological Class Antibacterial Combination Product
General Purpose Treatment of Bacterial Infections
Origin Synthetic Combination

What Type of Medicine is Moxzole and What is it Made Of?

Moxzole is a synthetic, fixed-dose combination (FDC) medicine classified as a potent antibacterial combination product and is dispensed by prescription. It is universally identified by the generic name co-trimoxazole or the shorthand TMP-SMX. Co-trimoxazole is a potent antimicrobial agent used against susceptible bacteria. This compound is clinically recognized for its broad application against a range of microbial organisms.

The medicine is composed of two distinct active pharmaceutical ingredients: Sulphamethoxazole and Trimethoprim. This pairing places Moxzole into the high-level pharmacological class of a sulfonamide combined with a dihydrofolate reductase inhibitor. The co-trimoxazole formulation is well-established, also appearing in popular trade names such as Bactrim and Septra. This single product is manufactured in various pharmaceutical preparations, including an oral dosage form such as a tablet or oral suspension, and an intravenous solution, allowing for systemic use via the oral or intravenous route of administration.


Moxzole's General Therapeutic Purpose and Dual-Action Principle

The general purpose of Moxzole is to function as an effective antimicrobial agent used to eliminate bacterial infections caused by susceptible microbial organisms. It utilizes a specialized synergistic effect to neutralize the threat. For instance, the combination is typically reserved for instances where a potent, dual-mechanism approach is required to resolve an active infection.

This synergistic principle stems from its dual composition, which is engineered to target two essential steps in the bacterial life cycle simultaneously. Sulphamethoxazole interferes with the bacteria's initial creation of folic acid, a compound vital for bacteria to create their genetic material, while Trimethoprim subsequently blocks a key enzyme needed for the final processing of that folic acid. This strategic two-pronged approach, known as sequential block inhibition, aims to deliver a stronger, often bactericidal (bacteria-killing) result against the bacteria than either ingredient could achieve if administered alone. This combination is classified as an essential medicine, with reliable action against numerous bacterial threats and acceptance in healthcare systems globally.

Regulatory References

  1. NIH: Trimethoprim Sulfamethoxazole - StatPearls
  2. WHO Essential Medicines List Entry for Co-trimoxazole

What side effects are possible with Moxzole?

Possible side effects and safety information

The safety profile for Moxzole (co-trimoxazole) is formally documented in government regulatory labeling, organizing potential adverse reactions by the body systems they affect and their frequency of occurrence. Safety events are classified from Very Common to Not Known, reflecting data gathered from clinical trials and post-marketing experience.

Classification Examples of Adverse Reactions (SOC)
Very Common Hyperkalaemia (Metabolism and nutrition)
Common Nausea, Diarrhoea (Gastrointestinal); Rash (Skin); Headache (Nervous system)
Very Rare Agranulocytosis, Aplastic Anaemia (Blood); SJS, TEN (Skin); Fulminant hepatic necrosis (Hepatobiliary)

The most frequent events often relate to the Gastrointestinal system or manifest as a non-specific Rash. However, the label explicitly documents the potential for rare, yet serious, adverse reactions, including severe cutaneous adverse reactions (SCARs) like Stevens-Johnson syndrome (SJS) and critical blood disorders such as Agranulocytosis.

Official documents outline specific safety constraints related to patient status. The medicine is contraindicated in infants less than 2 months of age due to the risk of kernicterus and in individuals with documented severe hepatic damage or severe renal insufficiency where monitoring cannot be performed. Older adults are officially noted to be at an increased risk for serious effects, particularly severe skin reactions and electrolyte imbalances like Hyperkalaemia. Furthermore, the regulatory safety notes advise that the risk of severe cutaneous reactions is highest during the initial weeks of therapy, and immediate discontinuation is necessary at the first appearance of rash, as defined in the official prescribing information.

Overdose and Emergency Response

Moxzole overdose is characterized by documented acute clinical manifestations, primarily affecting the gastrointestinal and nervous systems. Initial signs often include nausea, vomiting, loss of appetite, dizziness, and confusion. The regulatory profile notes that acute exposure can lead to severe and potentially life-threatening outcomes. Of specific concern is bone marrow depression, which is linked to high levels of the Trimethoprim component. Rare but officially documented severe reactions include fulminant hepatic necrosis and serious blood dyscrasias like agranulocytosis.

When to Seek Urgent Medical Help

Immediate medical attention is a mandatory regulatory requirement for all suspected overdoses. Urgent help must be sought by calling emergency services if the individual collapses, experiences a seizure, has trouble breathing, or cannot be awakened. The poison control helpline should also be contacted.

Management involves general symptomatic and supportive treatment. For documented bone marrow depression, the official countermeasure is the administration of Folinic acid (Leucovorin) to help restore blood cell production. Procedures like gastric lavage or haemodialysis may be considered in severe, acute cases, as the compound is moderately dialysable. Special caution is noted for elderly patients and those with existing kidney or liver impairment, as they are officially recognized to have an increased susceptibility to severe overdose effects.

Therapeutic Uses of Moxzole

Moxzole's Main Uses and Key Benefits

Moxzole is generally used across domains where additional symptomatic support is needed, providing support that helps ease the overall symptom burden during difficult episodes. The medication (or its therapeutic class) is commonly used across conditions presenting with acute episodes, where supportive symptom management is appropriate. This covers general clinical scenarios involving conditions characterized by periods of heightened symptoms or systemic stress.

The medicine is relevant for easing discomfort linked to episodic or fluctuating manifestations and helps address symptom clusters that may become intense or disruptive, applied when symptoms create noticeable functional strain. It offers symptomatic relief that helps patients cope more steadily. The medicine is commonly used to help with symptoms related to heightened physiological activity and functional stress.

“Moxzole is applied in contexts where additional symptomatic support is needed, contributing to improved comfort during symptomatic periods.”


Quick Fact

Quick Fact: For Disruptive Symptoms (The medicine may assist with maintaining functional stability when symptoms interfere with routine activities.)

Regulatory References

  1. NIH MedlinePlus overview on its drug class

Eligibility and Restrictions for Use

Moxzole (co-trimoxazole) is an antibacterial combination medicine subject to specific population eligibility rules documented by regulatory authorities. The primary constraints are related to age, hypersensitivity, and the functional status of certain organs.

Eligibility Scope Official Regulatory Status
Populations Allowed Adults and children 2 months of age and older are approved for standard labeled use.
Populations Contraindicated Infants less than 2 months of age must not use this medicine due to the risk of hyperbilirubinemia.

Contraindications and Restrictions

Use of Moxzole is prohibited in individuals with known hypersensitivity to trimethoprim or sulfonamides. The medicine is also strictly contraindicated for patients with:

  • Severe hepatic damage or severe liver parenchymal disease.
  • Severe renal insufficiency (typically CrCl <15 mL/min).
  • Megaloblastic anemia due to folate deficiency.
  • A history of drug-induced immune thrombocytopenia caused by sulfonamides/trimethoprim.
  • Acute porphyrias.

Conditional Use and Special Populations

Other groups are subject to conditional use as described in the official label:

  • Renal Impairment: Patients with moderate renal impairment (CrCl 15–30 mL/min) are restricted to a reduced dose.
  • Older Adults: The elderly are eligible but require special caution and monitoring due to increased susceptibility to adverse reactions and potential for compromised organ function.
  • Pregnancy/Lactation: Use is not recommended during pregnancy (especially late term) and is contraindicated while breastfeeding infants who are under 2 months old or are jaundiced/ill.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information describes the interaction structure of Moxzole (co-trimoxazole) across pharmacokinetic, pharmacodynamic, and formal restriction domains. All factual statements are based strictly on regulatory documents from government health authorities.

Interaction Classifications and Restrictions

The co-administration of Moxzole with Dofetilide is formally contraindicated by regulatory agencies. Co-administration with Methenamine is also officially not recommended.

Interaction Type Interacting Substance Examples Officially Documented Outcome
Exposure-Modifying Phenytoin, Warfarin, Digoxin, Lamivudine mathbfIncreased plasma exposure and mathbfreduced clearance of the co-administered drug
Pharmacodynamic Methotrexate, ACE Inhibitors, Potassium-Sparing Diuretics mathbfAdditive effects resulting in increased risk of toxicity (e.g., hyperkalaemia, haematological toxicity)
Transporter-Based Creatinine, Amantadine, Procainamide Trimethoprim component mathbfdecreases renal tubular secretion of the substance

Population and Non-Drug Interactions

The label notes that mathbfelderly patients have a higher documented risk for certain interactions, including mathbfthrombocytopenia when co-administered with thiazide diuretics, and mathbfincreased plasma digoxin levels. While there are no official mathbftiming separation rules for co-administration, the use of alcohol (ethanol) is generally not recommended, and Folinic Acid is known to interfere with Moxzole's antimicrobial efficacy.

Mechanism of Action

How Moxzole Works


Blocking Essential Bacterial Enzyme Activity

Moxzole is characterized as a bacterial inhibitor that primarily targets two essential enzymes within the susceptible organism: DNA Gyrase (Topoisomerase II) and Topoisomerase IV. The drug acts by directly inhibiting the function of both enzymes, which are critical for managing the bacterial cell's genetic material. This dual targeted enzyme inhibition initiates the molecular cascade that determines the drug's activity.

Interrupting DNA Maintenance and Separation

The mechanism involves a specific action on the nucleic acid pathway. By binding to the DNA-enzyme complex, Moxzole prevents the essential steps of DNA unwinding, repair, and final separation of the daughter chromosomes necessary for cell division. This interference with fundamental reproductive processes alters the regulation of bacterial growth.

Triggering Rapid Bacterial Cell Death

The ultimate physiological effect is the bactericidal (cell-killing) outcome. The comprehensive DNA damage caused by the dual enzyme blockade is non-reversible, leading quickly to the physiological demise of the invading organisms. This mechanism results in the termination of the target organism's replicative capacity.

Dosage and Administration Information

How to Use Moxzole

Moxzole (co-trimoxazole or TMP-SMX) is an antibacterial combination product whose administration must strictly follow the procedural guidelines detailed in prescribing information. These instructions dictate the official route, dose, frequency, and duration of use.


Official Routes and Standard Dosing

Moxzole is officially administered by two routes, depending on the dosage form:

  • Oral: Utilizing the tablet or oral suspension forms.
  • Intravenous (IV) Infusion: Using the intravenous solution, typically reserved for severe infections or patients unable to take the medicine by mouth.

The standard adult dose for acute bacterial infections is 160 mg of Trimethoprim (TMP) combined with 800 mg of Sulphamethoxazole (SMX), taken every 12 hours. Treatment duration is typically a minimum of five days, continuing until the patient has been symptom-free for two days.


Administration Conditions and Adjustments

Specific instructions must be followed for the correct use of Moxzole:

Condition Official Instruction
With Food/Water Best taken with a full glass of water; may be taken with some food or drink to minimize GI upset.
Fluid Intake Adequate fluid intake must be maintained throughout the treatment course.
IV Administration Solution must be diluted immediately and infused slowly over 60 to 90 minutes; rapid injection is forbidden.
Renal Adjustment Dosage must be reduced by half for adults with creatinine clearance between 15 and 30 mL/min.
Age Restriction Not recommended for infants under 6 weeks of age.

These instructions standardize the administration process, ensuring the medicine is delivered correctly according to specified guidelines.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Moxzole

This section provides a descriptive overview of the clinical research and evidence structure for Moxzole, which was studied for conditions such as acute exacerbations of chronic bronchitis (AECB), urinary tract infections (UTIs), Pneumocystis jirovecii pneumonia (PJP), and acute otitis media (AOM). The research describes the study designs used, the patient groups evaluated in the trials, and the outcomes that were monitored, such as those related to physical discomfort or microbiological change. Studies help show what has been observed so far, but research does not determine whether an individual will respond similarly. The following sub-sections detail the evidence for each condition, including what is known about long-term follow-up and areas where data are still emerging or uncertain.


Evidence for Use in Acute Exacerbations of Chronic Bronchitis (AECB)

Research has explored the use of Moxzole in adult patients experiencing a temporary worsening of chronic bronchitis. These short-term Randomized Controlled Trials (RCTs) examined patients during periods of increased symptom activity and focused on outcomes related to physical discomfort, specifically measuring changes in symptoms like cough and breathing difficulty. Studies examined the time interval until a specific measure of symptom stability was reached. Findings describe patterns observed in the studies over the course of treatment, typically 10 to 14 days, with many studies describing that the pre-defined primary outcome measures were met in the observed populations. However, follow-up durations were limited, meaning long-term effects are not fully established.


Long-Term Studies and Follow-Up Data

This section summarizes what is known about the research beyond the immediate treatment period. For most indications, the follow-up durations were limited to the short or intermediate term, focusing primarily on whether the acute episode resolved. Dedicated studies exploring the long-term outcomes or duration of observed outcomes (how long the treatment effect lasts) for Moxzole are still emerging or evidence is limited. Consequently, the long-term effects are not fully established across the indications studied.

Key Studies & References NICE Guideline: Acute exacerbation of chronic obstructive pulmonary disease (Reference for AECB management)

Frequently Asked Questions (FAQ)

Common questions about Moxzole (FAQ)


Q: How quickly does Moxzole start to have an effect?

A: Official information describes Moxzole as having a rapid, cell-killing (bactericidal) mechanism against susceptible bacteria. While the exact time varies, patient information sometimes notes that an improvement in infection symptoms may start to be observed within the first few days of beginning treatment.


Q: Is it normal to feel a change in my stomach when taking Moxzole?

A: Yes, official safety documents indicate that changes to the stomach and digestive system are commonly observed with this medicine. Nausea, vomiting, and diarrhea are frequently listed as common adverse reactions documented in the regulatory information.


Q: What should I do if I miss a dose of Moxzole?

A: Regulatory instructions often describe general procedures for a missed dose, typically advising that a dose be taken as soon as a patient remembers. If the time for the next scheduled dose is near, the previous dose is often advised to be skipped to maintain the regular schedule.


Q: What happens if I stop taking Moxzole suddenly?

A: Patient information from official sources emphasizes the importance of completing the full course of treatment as prescribed. Stopping a course of antibacterial medicine prematurely has been associated with the possibility that the infection may not be fully treated. Furthermore, incomplete courses of treatment are generally noted in regulatory documents as a factor that may encourage bacterial resistance.


Q: Can I drink alcohol while I am taking Moxzole?

A: Official guidance describes caution regarding the use of alcohol (ethanol) during the treatment period. Some official patient resources note this caution is related to the possibility of increasing side effects such as flushing, vomiting, or nausea.


Q: Is Moxzole generally used during pregnancy?

A: Regulatory guidance describes this medicine as generally not recommended during pregnancy, particularly in the later stages. This is often due to the described potential for effects on the developing fetus, which is noted in official prescribing documents.


Q: Can Moxzole interfere with birth control pills?

A: The official interaction documents for co-trimoxazole do not consistently list oral contraceptives as a formal, major interaction. However, official patient information generally reminds patients to inform a healthcare provider about all medications they are taking, including contraceptives.


Q: Why are there warnings about Moxzole and specific heart conditions?

A: Official safety documents list hyperkalaemia, which is abnormally high potassium levels in the blood, as a very common side effect. High potassium can potentially affect heart rhythm, which is why this risk is highlighted in the official warnings, particularly for specific patient groups like older adults.


Q: How long does Moxzole stay in your system after stopping it?

A: Official documents define the half-life of the active components, which is the time it takes for half of the medicine to be eliminated from the body. The half-lives of both active ingredients are described as approximately 8 to 11 hours in adults.


Q: Does Moxzole affect the results of any lab tests?

A: Yes, regulatory documents note that one of the active ingredients, Trimethoprim, can interfere with certain lab procedures. Specifically, it may interfere with a common method for determining serum creatinine, potentially leading to an overestimation of the actual creatinine values.


Q: Does Moxzole make you feel sleepy or drowsy?

A: Official safety documents list headache as a common side effect of the medicine. While some central nervous system effects are described in the regulatory documents, drowsiness or sleepiness is typically not listed as a common or very common adverse reaction.


Q: Are there any specific foods I need to avoid while on Moxzole?

A: Regulatory patient instructions generally describe that patients may maintain their normal diet unless otherwise directed by a healthcare professional. There are no blanket restrictions on specific food items in the regulatory patient guidance.


Q: Does Moxzole affect my blood pressure?

A: Regulatory documents list certain effects, such as the risk of high potassium levels (hyperkalaemia) and documented interactions with specific blood pressure medications, which are related to blood pressure regulation. However, the medicine is not commonly noted to directly cause significant changes in blood pressure itself.


Q: Is Moxzole a controlled substance?

A: Official government drug classifications identify this medicine as a prescription-only antibacterial agent. It is not currently listed as a controlled substance under the relevant regulatory schedules.


Q: Is it okay to take Moxzole with vitamins or supplements?

A: Official interaction documents note that one specific supplement, Folinic Acid, can interfere with the medicine's effectiveness. Official safety information generally reminds patients that a healthcare provider should be informed about all other products being used, including any vitamins and supplements.


Q: Do I need a special diet when taking Moxzole?

A: Regulatory patient instructions describe that patients may maintain their normal diet unless otherwise directed by a healthcare professional. Official guidance does specify the importance of adequate fluid intake.


Q: Can Moxzole be crushed or split if a person has trouble swallowing?

A: Regulatory guidance for the tablet form generally specifies that it should be swallowed whole. The official oral suspension (liquid form) is typically the preferred form for patients who have difficulty swallowing solid dosage forms.


Q: Does the time of day matter when taking Moxzole?

A: Official directions advise that the medicine should be taken at around the same time every day to maintain a consistent amount in the body. The typical schedule specified in regulatory documents is to take the dose every 12 hours.


Q: Is it true that Moxzole needs to be taken with food?

A: Official administration instructions state that the medicine is best taken with a full glass of water. The medicine may be taken with some food or drink, possibly to minimize the chance of stomach upset. However, official guidance does not typically describe that the medicine is required to be taken with food.


Q: Are there any long-term effects of taking Moxzole for several years?

A: Official research overviews generally describe that the follow-up periods in most clinical trials were limited to the short or intermediate term. Because of this, the long-term effects of taking the medicine for several years are not fully established in the formal research evidence.


Q: Does Moxzole have any effect on mental alertness or driving?

A: Official safety information lists nervous system effects, such as headache, which may affect a person's ability to drive or use machinery. Official patient resources note that awareness of individual response is important before performing tasks that require full mental alertness.


Q: What are the signs that Moxzole might not be working for me?

A: Patient instructions from official sources describe the importance of seeking guidance from a healthcare provider if symptoms are not observed to improve or if they appear to worsen during the initial period of treatment.


Q: Is it possible to be allergic to Moxzole after taking it for a while?

A: Official safety notes indicate that the risk of severe skin reactions, which can be part of an allergic response, is described as being highest during the initial weeks of therapy. This observation confirms that reactions can appear after the initial dose and are not limited to the very first day of use.


Q: Does Moxzole contain any ingredients I should be aware of, like lactose or gluten?

A: Official prescribing information contains a complete list of inactive ingredients, known as excipients, for each specific formulation of the drug. These details, which may include substances like lactose or gluten, are available in the formal product description provided by regulatory agencies.


Q: Do I need to check my blood work regularly while on Moxzole?

A: Official warnings and precautions advise that patients with certain pre-existing health conditions or those who are on long-term therapy may require regular monitoring. This monitoring can include blood work to check for potential blood disorders or electrolyte imbalances, as defined in regulatory documents.


Q: Can Moxzole cause hair loss?

A: Official safety documentation typically lists the full range of adverse reactions reported over time. Hair loss (alopecia) has been reported in post-marketing surveillance for co-trimoxazole, though it is generally not classified as a common adverse reaction in formal regulatory labeling.

How should Moxzole be stored and disposed of?

How to Store and Dispose of Moxzole?

Moxzole (co-trimoxazole) must be stored under specific environmental and safety conditions according to regulatory labeling.

Official Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically 68 F to 77 F (20 C to 25 C); do not freeze.
Protection Keep away from excess heat, moisture, and direct light.
Container Must be kept in the original, tightly closed, light-resistant container.
Child Safety Store out of the sight and reach of children in a secure location.

Disposal Instructions

Expired or unused Moxzole must not be disposed of in household waste or flushed down the toilet. Ask a pharmacist or healthcare professional about approved medicine take-back programs or follow specific FDA guidelines for proper disposal of the unused product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Moxzole found in:

A-Z Index: